WO2006138118A2 - Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds - Google Patents

Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds Download PDF

Info

Publication number
WO2006138118A2
WO2006138118A2 PCT/US2006/021993 US2006021993W WO2006138118A2 WO 2006138118 A2 WO2006138118 A2 WO 2006138118A2 US 2006021993 W US2006021993 W US 2006021993W WO 2006138118 A2 WO2006138118 A2 WO 2006138118A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
hiv
alkyl
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/021993
Other languages
English (en)
French (fr)
Other versions
WO2006138118A3 (en
WO2006138118B1 (en
Inventor
Shibo Jiang
Asim Kumar Debnath
Hong Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Priority to JP2008516935A priority Critical patent/JP2008543836A/ja
Priority to CA002608821A priority patent/CA2608821A1/en
Priority to EP06772346A priority patent/EP1896033A4/en
Publication of WO2006138118A2 publication Critical patent/WO2006138118A2/en
Publication of WO2006138118A3 publication Critical patent/WO2006138118A3/en
Publication of WO2006138118B1 publication Critical patent/WO2006138118B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the group heterocyclic stands for optionally substituted saturated, partially saturated, aromatic cyclics, which contain one or more heteroatoms selected from nitrogen, oxygen and sulfur and can also be benz-fused to an optionally substituted aromatic cyclic or heterocyles.
  • Substituents for aryl and heterocyclyl can be selected from those mentioned for alkyl .
  • This invention provides an antiviral pharmaceutical composition
  • an antiviral pharmaceutical composition comprising an effective amount of a compound with formula I, or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.
  • NB-206 and its analogs have potent inhibitory activity on infection by laboratory-adapted and primary HIV-I strains
  • T-20 targets the viral envelope glycoprotein gp41 (14,38,41,42).
  • T-20 like other peptides derived from the HIV-I gp41 CHR region, such as SJ-2176 (11,43) and C34 (17) , inhibits HIV-I fusion and entry. It has shown great promise against HIV replication in clinical trials (14,44). However, it has two major limitations: lack of oral availability (delivered by subcutaneous injection) and high cost of production (40) . Thus, development of small molecule HIV-I fusion inhibitors is urgently needed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PCT/US2006/021993 2005-06-15 2006-06-06 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds Ceased WO2006138118A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008516935A JP2008543836A (ja) 2005-06-15 2006-06-06 複素環置換フェニルフランおよび関連化合物を含む抗ウイルス組成物
CA002608821A CA2608821A1 (en) 2005-06-15 2006-06-06 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
EP06772346A EP1896033A4 (en) 2005-06-15 2006-06-06 ANTIVIRAL COMPOSITIONS WITH HETEROCYCLIC SUBSTITUTED PHENYLFURANES AND RELATED COMPOUNDS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69112005P 2005-06-15 2005-06-15
US60/691,120 2005-06-15

Publications (3)

Publication Number Publication Date
WO2006138118A2 true WO2006138118A2 (en) 2006-12-28
WO2006138118A3 WO2006138118A3 (en) 2007-07-26
WO2006138118B1 WO2006138118B1 (en) 2007-09-20

Family

ID=37570970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021993 Ceased WO2006138118A2 (en) 2005-06-15 2006-06-06 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds

Country Status (5)

Country Link
US (1) US20060287319A1 (https=)
EP (1) EP1896033A4 (https=)
JP (1) JP2008543836A (https=)
CA (1) CA2608821A1 (https=)
WO (1) WO2006138118A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502998A (ja) * 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
CN103402516A (zh) * 2010-06-17 2013-11-20 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
WO2024260445A1 (zh) * 2023-06-21 2024-12-26 上海科技大学 一种噻唑烷二酮类化合物、其药物组合物和其用途
US12421626B2 (en) 2018-06-29 2025-09-23 Fred Hutchinson Cancer Center Cell-stored barcoded deep mutational scanning libraries and uses of the same

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
WO2013159082A1 (en) 2012-04-20 2013-10-24 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN103724337A (zh) * 2012-10-15 2014-04-16 南京大学 一类含萘环和噻唑啉酮结构的吡唑啉类衍生物及其制法
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN111747944B (zh) * 2020-07-13 2022-09-30 复旦大学 广谱抗包膜病毒化合物、组合物及其应用
WO2022225572A1 (en) * 2021-04-22 2022-10-27 New York Blood Center, Inc. Respiratory virus inhibitors
CN115444846A (zh) * 2022-09-01 2022-12-09 中国人民解放军军事科学院军事医学研究院 HIV-1Tat蛋白抑制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27787A (id) * 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
US7241803B2 (en) * 2002-11-21 2007-07-10 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry
DE602004025708D1 (de) * 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
WO2005041951A2 (en) * 2003-10-28 2005-05-12 Rigel Pharmaceuticals, Inc. Rhodanine derivatives for use as antiviral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1896033A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502998A (ja) * 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
CN103402516A (zh) * 2010-06-17 2013-11-20 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
US12421626B2 (en) 2018-06-29 2025-09-23 Fred Hutchinson Cancer Center Cell-stored barcoded deep mutational scanning libraries and uses of the same
WO2024260445A1 (zh) * 2023-06-21 2024-12-26 上海科技大学 一种噻唑烷二酮类化合物、其药物组合物和其用途

Also Published As

Publication number Publication date
WO2006138118A3 (en) 2007-07-26
EP1896033A4 (en) 2010-12-22
EP1896033A2 (en) 2008-03-12
US20060287319A1 (en) 2006-12-21
WO2006138118B1 (en) 2007-09-20
JP2008543836A (ja) 2008-12-04
CA2608821A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
Jiang et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
Zhao et al. Identification of N-phenyl-N′-(2, 2, 6, 6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4
EP1896033A2 (en) Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
Lu et al. Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41
Jiang et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody
US20070232684A1 (en) Compounds for inhibition of HIV infection by blocking HIV entry
Liu et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
Schmidt et al. Small-molecule inhibitors of dengue-virus entry
Liu et al. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides
O’Keefe et al. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41
Kawasuji et al. Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore
An et al. Amino acid derivatives of the (−) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1
US20090176776A1 (en) Small molecule inhibitors of hiv-1 capsid assembly
WO2000055377A1 (en) SCREENING OF ANTIVIRAL COMPOUNDS TARGETED TO THE HIV-1 gp41 CORE STRUCTURE
Urvashi et al. Development of azaindole-based frameworks as potential antiviral agents and their future perspectives
Wang et al. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation
Zhang et al. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif–APOBEC3G complex
Zhao et al. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41
Qiu et al. N-substituted pyrrole derivative 12m inhibits HIV-1 entry by targeting Gp41 of HIV-1 envelope glycoprotein
Pan et al. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and-resistant HIV type 1 strains
TW200409629A (en) 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
Xu et al. Evaluation of “credit card” libraries for inhibition of HIV-1 gp41 fusogenic core formation
Garg et al. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion
Bailey et al. Disulfide sensitivity in the Env protein underlies lytic inactivation of HIV-1 by peptide triazole thiols
US20140179637A1 (en) Methods and compounds to inhibit enveloped virus release

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2608821

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006772346

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008516935

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE